Literature DB >> 4015398

Phthalates and organophosphorus compounds as cholinesterase inhibitors in fractions of industrial hexane impurities.

J L Vicedo, M Pellín, E Vilanova.   

Abstract

Cholinesterase (ChE) inhibitors have been described in the distillation residue of hexane and other industrial solvents. The residue of a commercial hexane has been fractionated by preparative chromatography. The anticholinesterase (antiChE) activity was isolated in two fractions (F-5, F-7) which contained only 0.61 and 0.16% respectively of the original dry weight hexane residue. In the former fraction, reversible and irreversible progressive inhibition was observed, and organophosphorus compounds (OPs) were detected colorimetrically and by gas chromatography. This fraction was subfractionated in a second chromatographic step. One subfraction containing the highest antiChE activity and 88% phosphorus of F-5 was isolated. In this subfraction triphenylphosphate and other not definitely identified OP compounds were detected by gas chromatography/mass spectrometry, together with several adipates and phthalates, including di-n-butylphthalate. This phthalate could explain the reversible inhibition of ChE by the hexane residue, and triphenylphosphate and the unidentified OP the irreversible inhibition. A possible toxicological role of these impurities is discussed in relation to occupational neuropathies by exposure to solvents.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4015398     DOI: 10.1007/bf00286574

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  9 in total

1.  Neurotoxic and biochemical properties of some triaryl phosphates.

Authors:  W N ALDRIDGE; J M BARNES
Journal:  Biochem Pharmacol       Date:  1961-05       Impact factor: 5.858

2.  A new and rapid colorimetric determination of acetylcholinesterase activity.

Authors:  G L ELLMAN; K D COURTNEY; V ANDRES; R M FEATHER-STONE
Journal:  Biochem Pharmacol       Date:  1961-07       Impact factor: 5.858

3.  [Clinical and experimental observations on so-called polyneuritis caused by tricresylphosphates].

Authors:  A Capellini; G Chiappino; N Zurlo
Journal:  Med Lav       Date:  1968-12       Impact factor: 1.275

4.  A comparative study of the toxicity of n-pentane, n-hexane, and n-heptane to the peripheral nerve of the rat.

Authors:  Y Takeuchi; Y Ono; N Hisanaga; J Kitoh; Y Sugiura
Journal:  Clin Toxicol       Date:  1981-12       Impact factor: 4.467

Review 5.  The enlarging view of hexacarbon neurotoxicity.

Authors:  P S Spencer; H H Schaumburg; M I Sabri; B Veronesi
Journal:  Crit Rev Toxicol       Date:  1980-10       Impact factor: 5.635

Review 6.  Organophosphorus esters causing delayed neurotoxic effects: mechanism of action and structure activity studies.

Authors:  M K Johnson
Journal:  Arch Toxicol       Date:  1975-12-18       Impact factor: 5.153

7.  Serum cholinesterase inhibitors in the commercial hexane impurities.

Authors:  E Vilanova; J L Vicedo
Journal:  Arch Toxicol       Date:  1983-05       Impact factor: 5.153

8.  Polyneuritis incidence in shoe factory workers: cases report and etiological considerations.

Authors:  A Cavalleri; V Cosi
Journal:  Arch Environ Health       Date:  1978 Jul-Aug

9.  Neurotoxic metabolites of "commercial hexane" in the urine of shoe factory workers.

Authors:  L Perbellini; F Brugnone; E Gaffuri
Journal:  Clin Toxicol       Date:  1981-12       Impact factor: 4.467

  9 in total
  2 in total

1.  Cholinesterases in blood plasma and tissues of rats treated with n-hexane or with its neurotoxic metabolite 2,5-hexanedione.

Authors:  A Bastone; N Frontali; C Mallozzi; M Sbraccia; L Settimi
Journal:  Arch Toxicol       Date:  1987-12       Impact factor: 5.153

2.  Sensitivity to tri-o-cresylphosphate neurotoxicity on n-hexane exposed hens as a model of simultaneous hexacarbon solvent and organophosphorus occupational intoxication.

Authors:  M Pellín; J L Vicedo; E Vilanova
Journal:  Arch Toxicol       Date:  1987-02       Impact factor: 5.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.